We give our take on today’s H1 report from Nexstim.
Intäkterna under andra kvartalet uppgick till 172 mkr (140 mkr), vilket motsvarar en tillväxt om ca.
Calliditas has secured a directed share issue of 2.
Redeye reiterates its Base Case of SEK 167 following Xbrane’s Q2 report.
Intellego meddelade under tisdagen den 10 augusti att de ingått ett icke exklusivt LOI (avsiktsförkl...
Enersense’s Q2 report didn’t offer many surprises. Enersense’s operations and strategy seem to proceed pretty much according to plan.
Redeye lowers its Base Case after reviewing Artificial’s Q2 report.
The leading supplier of liquid cooling technology, Asetek, released soft Q2 earnings and downgraded ...
Ahead of Q2, we make minor estimate changes mainly pertaining to supply-chain disruptions within Dynavox peaking, although we expect most of...
Vi följer upp vår tidigare kommentar efter Irlabs licensavtal med Ipsen, där vår syn var att avtalet...
Redeye remains positive to Transtema following a solid Q2 report, conforming the successful transfor...
Idag offentliggjorde Sensec sin delårsrapport för andra kvartalet 2021.
Q2 sales and EBIT are ahead of our expectations. Sales came in at SEK 177m; 6% above our estimates a...
Suominen reported higher than expected earnings in Q2 and provided some more colour on the reasons f...
Q2 EBIT SEK 17m, -9% vs. ABGSCe Strong outlook for ‘22e intact 8x ’22e EV/EBIT including German cont...
Redeye returns with a follow-up note to Genovis’ Q2’21 report and continues to have a positive long-...
Suominen’s Q2 margins remained strong, but focus is now on the color Suominen provides on demand slo...
Gofore’s EBITA/adj. EBITA of EUR 6.8m/6.9m in H1 were rather in line with expectations (Evli 7.
Solteq grew faster than expected in Q2, with Solteq Digital returning to clear growth.
Pihlajalinna’s revenue and profitability continued to improve and were slightly above estimates.
While Transtema was an active acquirer in 2016-18, making 16 acquisitions, it has not made any since...
Despite in line revenues, Rovio's Q2 report missed on adjusted EBIT due to high user acquisition spe...
Relais reported H1 EBITA of EUR 12.2m, slightly below our expectations.
Redeye comments on the positive update for remetinostat in basal cell carcinoma.
We are encouraged by early indicators of the growing value of the Freja eID ecosystem, with 200k+ us...
Record-breaking EBIT of SEK 144m (+10% vs. cons) ’21-23e EBIT up by 3%, driven by raised CS estimate...
